Asserting a brand new publication for Acta Materia Medica journal. Immune checkpoint inhibitors (ICIs) have revolutionized most cancers therapy however pose a problem of immune-related opposed occasions (irAEs), significantly endocrine toxicity, that may severely compromise affected person well-being. Present analysis has usually been restricted in scope and has not offered complete security profiles throughout the varied vary of ICI therapies.
The authors of this text handle this hole by performing a community meta-analysis on 55 randomized managed trials involving 32,522 sufferers. Utilizing STATA to calculate the floor below the cumulative rating curve, we ranked the protection of varied ICI monotherapies and mixture therapies. ICIs had been discovered to extend the chance of endocrine toxicities, corresponding to hypothyroidism, hyperthyroidism, hypophysitis, thyroiditis, and adrenal insufficiency; this threat was better with twin ICI regimens. Particularly, cytotoxic T lymphocyte related antigen-4 (CTLA-4) inhibitors, corresponding to ipilimumab, are carefully related to hypophysitis, whereas programmed cell death-1 (PD-1)/programmed cell loss of life ligand-1 (PD-L1) inhibitors, notably pembrolizumab and nivolumab, predispose sufferers to thyroid-related dysfunction, corresponding to hyperthyroidism, hypothyroidism, and thyroiditis. Apparently, nivolumab confirmed no elevated threat of adrenal dysfunction, in distinction to the elevated threat noticed with different ICI remedies.
This examine gives essential evidence-based insights for optimizing the risk-benefit stability of ICI therapies in scientific follow.
Supply:
Journal reference:
Ouyang, P., et al. (2024) Endocrine toxicity of immune checkpoint inhibitors: a community meta-analysis of the present proof. Acta Materia Medica. doi.org/10.15212/AMM-2023-0037.
